Innovate Biopharmaceuticals, Inc. (INNT) Company Bio
Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. Its late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease (IBD), and nonalcoholic steatohepatitis (NASH). The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease. It is also developing INN-108, which is entering into Phase 2 clinical trials for the treatment of mild to moderate ulcerative colitis. In addition, the company owns the global rights to INN-329, a proprietary formulation of secretin, a peptide hormone used to enhance visualization in magnetic resonance cholangiopancreatography procedures. Innovate Biopharmaceuticals, Inc. was founded in 2012 and is based in Raleigh, North Carolina.
Global concerns over the spread of the novel coronavirus rocked stock markets on Monday. The spread of COVID-19 has been a major economic punch felt around the globe, and it's impacting production at Triangle firms – from Lenovo to Cree.
Highlighting Larazotide's Effect across the Gut-Vascular Barrier - a Fundamental Disease Mechanism in a Variety of Autoimmune and Inflammatory Diseases RALEIGH, NC / ACCESSWIRE / February 19, 2020 / Innovate ...
RALEIGH, NC / ACCESSWIRE / February 18, 2020 / Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT - "Innovate"), a clinical stage biotechnology company focused on developing novel therapeutics announced the results from its February 14, 2020 special meeting of shareholders to approve proposals related to its upcoming merger with RDD Pharma Ltd. ("RDD").
TEL AVIV, Israel and RICHMOND, Calif., Nov. 13, 2019 /PRNewswire/ -- RDD Pharma, Ltd. ("RDD"), a company focused on orphan and innovative therapies for gastrointestinal disorders entered into a non-binding letter of intent ("LOI") to acquire Naia Rare Diseases ("Naia"), a biopharmaceutical company developing drugs for Short Bowel Syndrome ("SBS") and other rare gastrointestinal diseases. Closing of the transaction is anticipated to occur after the consummation of the proposed merger of RDD and Innovate Biopharmaceuticals, Inc. (INNT) which will form a combined company (the "INNT Merger") intended to be named 9 Meters Biopharma, Inc. In exchange, Naia will receive a combination of cash and shares in 9 Meters Biopharma subject to closing of the INNT Merger.